MedTrace Logo

Early Detection of COPD Exacerbations Using Home Monitoring Device

NCT07554352 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-08-10

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the safety and effectiveness of a home-monitoring device (RespirAI) in the early detection of COPD exacerbations in adults (age \>21) with physician-diagnosed COPD who are at high risk for exacerbations. The study will collect data from participants with COPD that will be analyzed using an AI-based algorithm to predict exacerbation events. The device's predictions will then be compared against clinically documented exacerbations to assess detection accuracy.

Conditions

  • COPD Exacerbation

Interventions

DEVICE

RespirAI

Use of a software-based monitoring device for 6 months.

Sponsors & Collaborators

  • RespirAI US Inc

    lead INDUSTRY

Principal Investigators

  • Adam D Wells, MD, FCCP · Nebraska Methodist Hospital

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-05
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07554352 on ClinicalTrials.gov